Why Marijuana Companies Are Rebranding Themselves As Health Care Companies

By Brendan Bures.

Investing in marijuana stocks isn’t a simple proposition. Guides can help lead you down the right path and it’s important to know what a cannabis company doe —tech? processing? distribution? — before investing. Even though marijuana has convinced millennials to buy stocks again, companies understand the stigma and volatility surrounding the market currently.

Which perhaps explain why two of the biggest marijuana companies in North America are rebranding themselves to potential investors. According to Barron’s, marijuana executives at Canopy Growth and Aurora Cannabis want investors to consider them alongside other health care stocks, not weed stocks.

Don’t forget that medical marijuana still drives a significant portion of their business, executives said to investors at a major health care conference put on by Jefferies, an investment bank.

“Our pedigree is as a medical cannabis company,” Aurora Chief Corporate Officer Cam Battley told Barron’s. “That opens doors for us on a global basis. When we need to meet with the top regulators or policy makers in country after country, that is incredibly helpful.”

Barron’s noted that marijuana company executive stood out against the crowd of health care businessmen and investors, emphasizing the casual in their business casual dress. But the marijuana guys didn’t back down from the competition, either. They have a place in the health care market, they argued, especially in helping patients where modern medicine cannot with ailments like chronic pain, anxiety, and bowel diseases.

“We see very clearly the largest economic opportunity over the next several years will be in the global medical cannabis sector,” Battley said.

Photo by Javier Hasse.

This article was originally posted on The Fresh Toast.

Related Stories:

Here's What CBD Can't Do For You

Marijuana Vs. Hemp: What's The Difference?

The preceding article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.